Table 3.
The hematological effects of the human Wharton’s jelly mesenchymal stem cells -secretome on breast cancer bearing mice
| Groups | |||||||
|---|---|---|---|---|---|---|---|
| Parameters | Non-tumor (secretome) | Non-tumor (healthy) | PBS (tumor-bearing) |
Cisplatin-treated | Secretome treated (20 mg/ml) |
P-value * | |
| WBC (10 3 /µl) | 4.5 ± 0.5 | 4.2 ± 0.5 | 3.6 ± 0.4 | 4.2 ± 0.2 | 4.8 ± 0.5 | 0.143 | |
| Lymphocytes (%) | 68.4 ± 3.1 | 66.4 ± 3.1 | 53 ± 12.4 | 65 ± 13.4 | 66 ± 10.4 | 0.012 | |
| Neutrophils (%) | 30 ± 9.2 | 33 ± 9.2 | 45 ± 16.5 | 34 ± 10.5 | 33 ± 14.7 | 0.005 | |
| Monocytes (%) | 1.8 ± 0.6 | 1.3 ± 0.6 | 1.8 ± 0.5 | 1.3 ± 0.6 | 1.2 ± 0.6 | 0.675 | |
| Eosinophils (%) | 0.4 ± 0.4 | 0.6 ± 0.4 | 0.8 ± 0.6 | 0.5 ± 0.5 | 0.6 ± 0.5 | 0.568 | |
| Basophils (%) | 0.1 ± 0.1 | 0.3 ± 0.5 | 0.5 ± 0.4 | 0.4 ± 0.3 | 0.3 ± 0.3 | 0.812 | |
| RBC (10 6 /µl) | 7.9 ± 0.9 | 8.1 ± 0.9 | 7.8 ± 0.6 | 8 ± 0.4 | 7.6 ± 1.0 | 0.124 | |
| HGB (g/dl) | 13.9 ± 1.0 | 13.2 ± 1.0 | 12 ± 0.5 | 12.6 ± 0.8 | 13.1 ± 0.6 | 0.118 | |
| HCT (%) | 44 ± 4.0 | 45 ± 4.0 | 41.8 ± 6.2 | 48.3 ± 5.75 | 44.7 ± 4.2 | 0.954 | |
| MCV (fl) | 66.1 ± 2.0 | 64.2 ± 1.5 | 66 ± 2.7 | 66.5 ± 6.75 | 66.5 ± 1.7 | 0.015 | |
| MCH (pg) | 22.1 ± 0.8 | 20.4 ± 0.6 | 21.5 ± 1.0 | 21 ± 2.5 | 21.5 ± 2.1 | 0.975 | |
| MCHC (g/L) | 34 ± 1.0 | 34.5 ± 1.2 | 36.8 ± 1.2 | 34.2 ± 1.7 | 35 ± 2.5 | 0.012 | |
| RDW (%) | 14.1 ± 0.5 | 11.1 ± 0.5 | 13.5 ± 1.2 | 13.4 ± 1.7 | 12.9 ± 1.5 | 0.010 | |
| Platelets (10 3 /µl) | 747 ± 135 | 849 ± 140 | 673 ± 192 | 735 ± 190 | 752 ± 130 | 0.048 | |
Data are expressed as the Mean±SD. * Kruskal-Wallis test was performed and the differences compared with the untreated tumor bearing animals (PBS). Values are statistically significant at P≤0.05
WBC: White blood cell; RBC: Red blood cell; HGB: Hemoglobin; HCT: Hematocrit; MCV:Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; RDW: Red cell distribution width; PBS: Phosphate-buffered saline solution